XOMA Royalty Corporation (NASDAQ:XOMA) Sees Significant Increase in Short Interest

XOMA Royalty Corporation (NASDAQ:XOMA) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 482,452 shares, an increase of 31.7% from the November 30th total of 366,222 shares. Based on an average daily volume of 93,126 shares, the short-interest ratio is presently 5.2 days. Approximately 4.2% of the company’s stock are short sold. Approximately 4.2% of the company’s stock are short sold. Based on an average daily volume of 93,126 shares, the short-interest ratio is presently 5.2 days.

Analysts Set New Price Targets

Several research firms have recently issued reports on XOMA. HC Wainwright decreased their price target on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Wall Street Zen lowered XOMA Royalty from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. UBS Group set a $76.00 price target on XOMA Royalty in a report on Tuesday, December 9th. Zacks Research lowered shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $60.60.

XOMA Royalty Stock Performance

Shares of NASDAQ XOMA opened at $26.18 on Wednesday. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92. The company has a market cap of $324.11 million, a P/E ratio of 35.38 and a beta of 0.94. The business’s 50 day moving average is $30.70 and its two-hundred day moving average is $31.12. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.33). The company had revenue of $9.35 million during the quarter, compared to analyst estimates of $11.47 million. XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%. On average, equities analysts expect that XOMA Royalty will post -1.41 EPS for the current year.

Insider Transactions at XOMA Royalty

In other XOMA Royalty news, CEO Owen Hughes acquired 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was purchased at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the completion of the acquisition, the chief executive officer owned 102,000 shares of the company’s stock, valued at approximately $2,555,100. This trade represents a 5,000.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its position in XOMA Royalty by 3,436.4% during the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after buying an additional 756 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 543 shares during the period. Raymond James Financial Inc. acquired a new position in shares of XOMA Royalty in the second quarter valued at $116,000. Finally, BNP Paribas Financial Markets lifted its position in XOMA Royalty by 266.6% in the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,346 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.